GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Cholestyramine oral suspension (QUESTRAN)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

QUESTRAN

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Nonabsorption does not eliminate acid-base precautions

The PREVALITE mirror identifies hyperchloremic acidosis concerns with renal insufficiency, volume depletion and spironolactone.

Before applying: Keep the qualitative warning visible; do not invent a clearance threshold or monitoring frequency.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - PREVALITE

Product / population
PREVALITE cholestyramine powder for oral suspension; brand-specific excipient and administration details must not be generalized to all products.
Renal measure
Qualitative renal insufficiency/volume depletion; no numeric cutoff

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Before using this finding

Lack of systemic absorption does not remove acid-base concerns.

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Renal dosing, restrictions and evidence limits

Prolonged use of this chloride-form anion-exchange resin can cause hyperchloremic acidosis. The mirror emphasizes caution in renal insufficiency, volume depletion and concurrent spironolactone, with particular concern for younger/smaller patients receiving relatively larger doses.

This is a qualitative renal-safety warning, not a numeric dose-reduction table. It remains relevant even when a separate source describes lack of systemic absorption. Fluid and electrolyte status and concomitant drugs require assessment; no new monitoring frequency or clearance cutoff is invented.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/prevalite-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

GlobalRPh RX List - PREVALITE

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - QUESTRAN

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

QUESTRAN oral suspension; source also discusses the light formulation, but no equivalence or strength conversion is inferred.

Renal method: Qualitative renal-insufficiency caution; no numerical renal dosing bands.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - PREVALITE

Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.
Before using this finding

Lack of systemic absorption does not remove acid-base concerns.

Dialysis evidence: No dialysis regimen established in selected content

PREVALITE cholestyramine powder for oral suspension; brand-specific excipient and administration details must not be generalized to all products.

Renal method: Qualitative renal insufficiency/volume depletion; no numeric cutoff
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Nonabsorption does not eliminate acid-base precautions

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

qualitative renal safety

Nonabsorption does not eliminate acid-base precautions

The PREVALITE mirror identifies hyperchloremic acidosis concerns with renal insufficiency, volume depletion and spironolactone.

How to use this: Keep the qualitative warning visible; do not invent a clearance threshold or monitoring frequency.

GlobalRPh RX List - PREVALITE

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - QUESTRANGlobalRPh RX List - PREVALITE
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/questran-drug/

Exact product and population

QUESTRAN oral suspension; source also discusses the light formulation, but no equivalence or strength conversion is inferred.

RDM35-SCOPE-cholestyramine-questran · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - QUESTRAN

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · QUESTRAN oral suspension; source also discusses the light formulation, but no equivalence or strength conversion is inferred.

Renal method: Qualitative renal-insufficiency caution; no numerical renal dosing bands.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Source recheck unresolved. Prior follow-up retrieval/version warning retained; not resolved by v6.0. Read source-review status
Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Prolonged treatment with this chloride-containing anion-exchange resin can cause hyperchloremic acidosis. The source calls for particular caution with renal insufficiency, volume depletion, or concomitant spironolactone; smaller/younger patients may also be vulnerable. This is a renal safety warning rather than a renal-clearance dose table. Separate other oral medicines by at least 1 hour before or 4 to 6 hours after cholestyramine to limit binding interactions.

RDM35-rxlist-cholestyramine-questran-8453cc8f05-C1 · Source locator: Precautions: General (hyperchloremic acidosis); Drug Interactions.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/questran-drug/
Retrieved
2026-09-07
Renal-function method
Qualitative renal-insufficiency caution; no numerical renal dosing bands.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
3a56c01dc7ab913df9bc86dbb4a7ba73b4462913f89b67f65cdf1ddc9485dd0f
Rxlist

GlobalRPh RX List - PREVALITE

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · PREVALITE cholestyramine powder for oral suspension; brand-specific excipient and administration details must not be generalized to all products.

Renal method: Qualitative renal insufficiency/volume depletion; no numeric cutoff
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualitative renal precaution. No complete numerical renal schedule is supplied by this selected finding.
Before using this finding

Lack of systemic absorption does not remove acid-base concerns.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Prolonged use of this chloride-form anion-exchange resin can cause hyperchloremic acidosis. The mirror emphasizes caution in renal insufficiency, volume depletion and concurrent spironolactone, with particular concern for younger/smaller patients receiving relatively larger doses.

This is a qualitative renal-safety warning, not a numeric dose-reduction table. It remains relevant even when a separate source describes lack of systemic absorption. Fluid and electrolyte status and concomitant drugs require assessment; no new monitoring frequency or clearance cutoff is invented.

RDM59-rxlist-cholestyramine-questran-59f0c58254-C1 · Source locator: Precautions: General

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/prevalite-drug/
Retrieved
2026-09-10
Renal-function method
Qualitative renal insufficiency/volume depletion; no numeric cutoff
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
320797d970800bf4e13624105cc948643819e375931e75f683e29ea31bb093a8

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/questran-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
6a6b6f6fcc598cabe6a4b607e194dc81cb0fad5c50b2c1a65ce5516f2134c819
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report